If abacavir is on the table, this test isn't optional. It's the rare case where a genetic screen heads off a specific — sometimes fatal — drug reaction, with a randomized trial behind it and effectively no downside: one blood draw, results in a week, valid for life. Outside the HIV context, it matters as the proof-of-concept the rest of pharmacogenomics still measures itself against.
The reaction was unforgettable: a high fever, a body-wide rash, and stomach symptoms landing people in hospital within their first two weeks on the drug. Before testing, somewhere between 5% and 8% of European-descent patients put on abacavir went through it. Some didn't recognize it as a drug reaction, restarted the medication after their fever broke, and went into a fast hypotensive crisis — a few of them died. Almost every one of those reactions carried the same gene variant, HLA-B*57:01.
The mechanism is one of the cleanest in pharmacology. Abacavir slips into a pocket on the HLA-B*57:01 protein — and no other version of that protein — and changes which bits of normal cellular protein the immune system sees on the cell surface. The immune system, trained to ignore the old set, treats the new set as foreign and attacks Illing 2012. The reaction is the body attacking itself for showing what looks like a stranger's ID badge.
Who actually needs this
If you're being started on any abacavir-containing HIV regimen — Ziagen on its own, Epzicom (called Kivexa in some countries), Trizivir, or Triumeq — this test should happen first. That's the whole audience for the test as a personal action item. Outside that context it's a literacy topic, not a personal one.
Ancestry shifts the odds of carrying the variant but doesn't change who gets tested. The allele is most common in people of European descent (around 5–8%) and parts of South Asia (up to about 14% in some Indian populations), less common in Hispanic and East Asian populations, and rare in people of sub-Saharan African ancestry (around 1–2%) Martin et al. 2014. Everyone gets tested anyway: self-reported ancestry is unreliable, mixed-ancestry people sit at intermediate frequencies, and the cost of guessing wrong is too high.
What happens if you skip it
For a non-carrier, nothing — you start the drug and you stay on it. For a carrier, the odds of a clinically diagnosed reaction within the first six weeks are roughly half to two-thirds, with onset usually within 11 days Mallal et al. 2008. Fever, body-wide rash, GI symptoms, deep fatigue. Most people recognize something is wrong and stop the drug; with prompt discontinuation, the first reaction is usually survivable.
The lethal scenario is the one nobody planned for. Symptoms get attributed to a stomach bug or a viral illness. The patient stops the drug for a couple of days, feels better, and restarts. The second exposure can drop blood pressure within hours. It's that scenario — re-challenge after an unrecognized first reaction — that drove the FDA's boxed warning and the decades-long push to get the test into routine practice FDA 2008.
How the test works
Your HIV clinician orders it, usually as part of baseline labs at the first visit so the result is on file well before any specific regimen is chosen. A single blood draw or cheek swab goes to a clinical lab; results come back as positive or negative for HLA-B*57:01 in one to seven days. The result is permanent and goes on your record — your DNA doesn't change.
Why this one test became the model for the field
Abacavir was approved in 1998. Within a few years, post-marketing reports made clear that a small but real fraction of patients were having severe — sometimes fatal — reactions. In March 2002 two papers landed in the same issue of The Lancet, from independent groups, both naming HLA-B*5701 as the marker Mallal et al. 2002 Hetherington et al. 2002. Some HIV practices began screening reactively.
The PREDICT-1 trial six years later — randomized, prospective, multinational — converted "looks like a marker" into "is the marker" Mallal et al. 2008. The FDA updated the abacavir label that summer FDA 2008. Formal prescribing guidelines from the Clinical Pharmacogenetics Implementation Consortium followed, and were updated as more data came in Martin et al. 2014. By the early 2010s the test was global standard of care.
That arc — mechanism, association, prospective trial, guideline, label — is the template every other genetic test for drug safety has tried to follow. Most have stumbled somewhere along it. HLA-B*57:01 got all the way through because the underlying biology happened to be unusually clean: one gene variant, one drug, one effective alternative sitting right there.
What people get wrong about it
A negative test is sometimes read as "any reaction in the first weeks means it's not abacavir." It doesn't. Non-carriers can still develop fevers, rashes, and GI symptoms in early treatment — usually from a viral illness, another drug, or something unrelated — and clinicians will still stop abacavir as a precaution if the picture looks ambiguous. The test rules out the specific immune reaction; it doesn't rule out everything else.
The reaction itself is often described as "just a rash" in casual summaries. It isn't. It's a whole-body delayed hypersensitivity reaction — fever, rash, GI, respiratory and circulatory symptoms together — and the dangerous feature is what happens on the second exposure, not the first. That's why even a single dose in a confirmed-positive carrier is the line that doesn't get crossed, ever.
Cost and access
In the U.S., cash price runs roughly $50 to $200. Practically nobody pays cash: insurance, Medicaid, Medicare, the Ryan White program, and state ADAPs all cover it as part of HIV care. The NHS, Australia's PBS, Canadian provinces, and most European public payers cover it routinely. Cost-effectiveness analyses across multiple health systems land comfortably on the side of "do it," because one serious hospitalization for a hypersensitivity reaction costs far more than running the screen on everybody Schackman et al. 2008.
Turnaround is fast enough that HIV treatment is almost never delayed by waiting for the result — most labs return it in 3–5 business days, some in 24 hours.
What changes
For most readers, nothing visible. You get a negative result, abacavir starts, and the test recedes into the background of your medical record. For the carriers — somewhere between 1% and 14% of the population depending on ancestry — the morning your result comes back positive is the morning a different drug gets prescribed. You don't notice the reaction that didn't happen. Your HIV treatment proceeds on a tenofovir-based combination that works just as well.
At a wider scale: an entire category of severe drug reaction stopped happening in HIV clinics. And the success of this one test pulled along a field. When oncologists screen for the DPYD gene before fluoropyrimidine chemotherapy, when neurologists screen for HLA-B*15:02 before carbamazepine in some Asian populations, when rheumatologists screen for HLA-B*58:01 before allopurinol, they're working from the playbook this test wrote.
Worth knowing next
Other genetic tests for drug safety follow the same logic but check different genes for different drugs — HLA-B*15:02 before carbamazepine in some Asian populations, HLA-B*58:01 before allopurinol, HLA-B*13:01 before dapsone. The broader category of testing-before-prescribing also covers TPMT and NUDT15 before thiopurine chemotherapy, DPYD before fluoropyrimidines, and CYP2C19 before clopidogrel. Same idea, different drugs, generally messier evidence than the abacavir case.
- — A rare case where a single genetic result directly, definitively changes a drug decision.
- — This single-gene check before an HIV drug is the flagship example of pharmacogenomic testing in practice.
- — Another single-gene result that tells a doctor which drugs are dangerous for you.
- — Like HLA-B*57:01 before abacavir, HLA-B27 is a one-and-done HLA test for a specific question.
Substance and claimed effects
HLA-B*57:01 testing is a one-time genetic screen that detects whether a person carries the HLA-B*57:01 allele, a variant of the class I major histocompatibility complex. The test is performed before initiating the HIV antiretroviral abacavir (Ziagen; component of Epzicom/Kivexa, Trizivir, and Triumeq). Carriers of HLA-B*57:01 are at very high risk of an immunologically mediated abacavir hypersensitivity reaction (HSR) that can be fatal on re-challenge. Prospective screening eliminates immunologically confirmed HSR by directing carriers to alternative regimens Mallal et al. 2008. The test is endorsed by the FDA boxed warning (since 2008) FDA 2008, the U.S. Department of Health and Human Services antiretroviral guidelines DHHS 2024, and the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline Martin et al. 2014. It is widely cited as the most successful clinical implementation of pre-prescription pharmacogenomics: a clean genotype-phenotype link, a near-100% negative predictive value, an effective alternative drug, and rapid regulatory uptake.
Evidence by addressing question
mechanism
HLA class I molecules present self-peptides to CD8+ T cells for immune surveillance. Abacavir binds non-covalently within the F-pocket of HLA-B*57:01 specifically — not within other closely related HLA-B alleles — altering the chemistry of the antigen-binding cleft Illing et al. 2012. This binding shifts the repertoire of self-peptides that the molecule presents to T cells; many novel self-peptides are loaded that the immune system has not been tolerized against Norcross et al. 2012. T cells encountering this altered self complex respond as if it were a foreign threat, driving the multi-organ inflammatory cascade of abacavir HSR.
This mechanism is unusual among HLA-drug associations. In most cases (e.g., HLA-B*15:02 / carbamazepine) the drug or a metabolite binds covalently to peptide or protein and is presented as a hapten. Abacavir's mode — non-covalent binding to the HLA cleft itself, modifying the self-peptidome — is a distinct paradigm. It explains both the exquisite specificity (a single HLA allele) and the high penetrance (most carriers immunologically prime on first exposure, and a majority develop clinical HSR).
evidence
The PREDICT-1 randomized controlled trial is the landmark study Mallal et al. 2008. 1,956 patients across 19 countries were randomized 1:1 to prospective HLA-B*57:01 screening (with carriers steered to alternative regimens) versus standard of care without screening. The primary endpoint of immunologically confirmed HSR (confirmed by skin patch test) was 0% in the prospective-screening arm versus 2.7% in the control arm (p<0.001). Clinically suspected HSR — a broader and less specific category — was reduced from 7.8% to 3.4%. The trial was effectively unblinded for screened carriers (who knew to avoid abacavir), so the immunologically confirmed endpoint, adjudicated by blinded patch testing, is the critical comparison.
The SHAPE study extended these findings Saag et al. 2008. Conducted partly in response to the concern that HLA-B*57:01 might predict HSR less well in non-white populations (where the allele is rarer), SHAPE retrospectively evaluated patch-test-confirmed HSR cases and showed ~100% sensitivity of HLA-B*57:01 in both white and black patients. Effectively, every patch-test-positive case in both groups carried the allele.
The original associations were two near-simultaneous retrospective case-control studies that converged independently on the same allele Mallal et al. 2002 Hetherington et al. 2002. Together — independent association discovery, mechanism characterization, prospective RCT with a clean clinical endpoint, multi-ethnic replication, cost-effectiveness analyses, and guideline integration — the evidence stack is among the most complete for any pharmacogenomic intervention.
protocol
The test is ordered by the prescribing clinician (typically an HIV specialist or infectious disease physician) before any abacavir-containing regimen is dispensed. A blood sample (or buccal swab in some labs) is sent to a clinical laboratory for PCR-based sequence-specific oligonucleotide typing or sequence-based typing. Turnaround time is typically one to seven days. Results are reported as positive or negative for HLA-B*57:01.
If positive: abacavir is contraindicated for life. The clinician selects an alternative NRTI backbone — most commonly tenofovir disoproxil fumarate or tenofovir alafenamide paired with emtricitabine (TDF/FTC or TAF/FTC). The result is documented in the patient's record and on any allergy list to prevent inadvertent re-prescription.
If negative: abacavir use is cleared. The CPIC guideline emphasizes that a negative result does not eliminate the need for clinical vigilance during early therapy — clinically suspected HSR can still occur from other causes, and the consensus is to monitor for symptoms over the first 6 weeks regardless Martin et al. 2014.
The test is one-time. HLA genotype does not change over the lifespan, and a documented negative or positive result remains valid permanently.
contraindications
The test itself has no contraindications — it is a minimally invasive sample with no procedural risk. The clinically actionable contraindication is to the drug, not to the test. A positive HLA-B*57:01 result is a permanent contraindication to abacavir; even a single dose of abacavir in a previously sensitized HLA-B*57:01 carrier can trigger a hypotensive, life-threatening reaction. The CPIC guideline classifies this as a strong recommendation with high evidence; abacavir labeling carries a boxed warning FDA 2008.
misconceptions
The most common misconception is that a negative HLA-B*57:01 test guarantees safety from any abacavir reaction. While immunologically confirmed HSR is essentially eliminated in non-carriers, clinically suspected HSR (rash, fever, GI symptoms within the first 6 weeks) can still occur — often driven by viral infections, other concomitant drugs, or non-HLA-B*57:01 idiosyncratic reactions. The negative predictive value for true HSR is functionally 100%, but the positive predictive value of clinical symptoms in a non-carrier is low; clinicians still monitor early therapy and may discontinue abacavir for any HSR-like presentation as a precaution Martin et al. 2014.
A second misconception is that abacavir HSR is "just a rash." It is a systemic delayed hypersensitivity reaction involving fever, rash, GI symptoms, malaise, and frequently respiratory or circulatory involvement. Re-challenge after a clinical HSR has historically caused fatalities — this is the reason for the boxed warning and for the bright-line rule against ever re-introducing the drug.
A third misconception is that ancestry can substitute for testing. Allele frequency varies widely, but ancestry self-report is unreliable, admixed populations carry intermediate frequencies, and the consequence of missing a positive is severe enough that the test is recommended in all populations regardless of background Martin et al. 2014.
audience
The direct audience is patients being considered for an abacavir-containing antiretroviral regimen — a subset of people living with HIV. Within that group, the test is universally recommended regardless of ancestry, age, or sex. Pediatric data are smaller in volume but consistent with adult findings, and the test is recommended for children starting abacavir.
The wider audience is anyone receiving HIV care, since they may be offered the test as part of baseline labs even before a specific regimen is chosen — many HIV clinics order HLA-B*57:01 at the first visit so the result is available whenever it becomes clinically relevant.
Outside the HIV treatment context, the test has limited individual relevance. The HLA-B*57:01 allele has weak associations with other phenomena (e.g., elite control of HIV viremia, possibly some autoimmune conditions), but none are clinically actionable at the level of a screening test.
practicalities
Cost is modest. In the U.S., cash price for HLA-B*57:01 typing ranges roughly $50–$200; in routine HIV care, the test is covered by Medicaid, Medicare, and commercial insurance, and is effectively bundled into baseline HIV labs. The Ryan White HIV/AIDS Program and most state ADAPs cover the test. National health systems (NHS, Australian PBS, Canadian provincial systems, most European public payers) cover the test uniformly.
Cost-effectiveness analyses have shown that HLA-B*57:01 screening is cost-effective by standard willingness-to-pay thresholds in U.S. and European settings — the upfront cost is dominated by the downstream cost of managing severe HSR (hospitalizations, drug substitutions, potential ICU admission) Schackman et al. 2008. In low-prevalence populations (East Asian, sub-Saharan African) the marginal cost-effectiveness is lower because the test catches fewer cases, but the per-event consequence justifies universal testing in nearly all settings.
Test turnaround is fast enough that HIV initiation is rarely delayed beyond the standard work-up window. Some clinical labs return results in 24 hours; most return in 3–5 business days.
history
Abacavir was approved by the FDA in 1998 as a nucleoside reverse transcriptase inhibitor for HIV. In post-marketing surveillance, an idiosyncratic hypersensitivity reaction emerged in roughly 5–8% of patients, occasionally fatal on re-challenge. Re-exposure deaths drove a regulatory focus on identifying the at-risk population.
In March 2002, two retrospective case-control studies were published simultaneously in The Lancet. The Australian group of Simon Mallal reported an extremely strong association between HLA-B*5701 and HSR in a Western Australian HIV cohort Mallal et al. 2002. The same week, a GlaxoSmithKline-led international group reported a similar finding in a broader population Hetherington et al. 2002. Reactive screening was adopted in many HIV practices over the following years, particularly in Australia and parts of Europe.
The PREDICT-1 RCT, published in 2008, provided the prospective evidence required for global adoption Mallal et al. 2008. The SHAPE study confirmed multi-ethnic generalizability the same year Saag et al. 2008. In July 2008, the FDA updated the abacavir label to recommend HLA-B*57:01 testing before initiation FDA 2008. The CPIC guideline formalized the prescribing recommendation in 2012 and updated it in 2014 Martin et al. 2014.
HLA-B*57:01 testing is now standard of care in HIV medicine globally and is one of the most-cited examples of clinical pharmacogenomics — a clean genotype-phenotype link, a clear actionable threshold, and an effective alternative drug. The pattern (mechanism → association discovery → prospective trial → guideline → regulatory action) is the template that other pharmacogenomic implementations have tried to follow, with mixed success.
stakes
Without testing, an HLA-B*57:01-positive patient starting abacavir faces a roughly 50–60% chance of developing a clinically diagnosed HSR within 6 weeks; immunologically confirmed reaction rates in carriers are in a similar range Mallal et al. 2008. Onset is typically within 11 days. Symptoms escalate from fever, rash, GI upset, and fatigue to respiratory and circulatory involvement.
The first reaction is usually survivable with prompt drug discontinuation. The lethal scenario is re-challenge: a patient whose symptoms were attributed to a viral illness or another drug, who restarts abacavir, can develop a rapid hypotensive crisis. Pre-screening era, re-exposure deaths were the principal regulatory concern. Even now, with screening universal in well-resourced settings, the boxed warning emphasizes the irreversibility of the contraindication once a true HSR has occurred.
payoff
For the typical non-carrier patient, the payoff is invisible — a negative result, abacavir started uneventfully, treatment proceeds. For the ~5–8% of European-descent (and variable by ancestry) carriers, the payoff is concrete: a serious illness is avoided, an equally effective alternative regimen (typically tenofovir-based) is substituted, and HIV treatment proceeds on schedule.
At a system level, HLA-B*57:01 screening eliminated the most predictable serious adverse reaction in HIV care. At a field level, the test established the precedent for pre-prescription pharmacogenomic screening: HLA-B*15:02 for carbamazepine in some Asian populations, HLA-B*58:01 for allopurinol, TPMT and NUDT15 for thiopurines, DPYD for fluoropyrimidines, CYP2C19 for clopidogrel. None of these have matched HLA-B*57:01 for cleanness of the genotype-phenotype link, but all owe part of their clinical adoption to the precedent.
The credibility range
Optimist case. HLA-B*57:01 testing is the strongest example we have of pharmacogenomic precision medicine working in practice. The mechanism is characterized at molecular resolution Illing et al. 2012. The prospective RCT showed complete elimination of immunologically confirmed HSR Mallal et al. 2008. Multi-ethnic validation demonstrated generalizability Saag et al. 2008. Cost-effectiveness is favorable. Regulatory and professional bodies (FDA, DHHS, CPIC, BHIVA, EACS) uniformly recommend the test. Clinical implementation is near-universal in well-resourced settings. The test prevents a serious — sometimes fatal — adverse drug reaction with near-100% negative predictive value. There is essentially no credible expert opposition; the open questions are about implementation in low-resource settings, not about the test's validity.
Skeptic case. The skeptic case is narrow but worth airing. (1) Clinically suspected HSR is reduced but not abolished; the false-positive rate of clinical diagnosis was historically high, meaning many "abacavir HSR" diagnoses in the pre-screening era were probably other things (infections, concomitant medications). The true magnitude of the pre-screening problem was likely smaller than reported. (2) The test is increasingly marginal as abacavir's role in modern HIV treatment declines — integrase-inhibitor-based regimens (especially bictegravir/TAF/FTC and dolutegravir-based combinations) have largely replaced abacavir in first-line therapy in well-resourced settings. The clinical relevance of the test continues to narrow at the population level even as it remains essential for the individual patient still receiving the drug. (3) HLA-B*57:01 is often cited as a pharmacogenomic success so often that it obscures the more sobering reality that most other pharmacogenomic targets have not yielded equally clean genotype-phenotype associations or equally usable drug substitutes — the "model" status may be misleading for other contexts.
Author's call. This is one of the closest things to a settled question in clinical pharmacogenomics. The test is high-evidence (PREDICT-1 RCT, multi-ethnic SHAPE replication, mechanism known), low-controversy (universal guideline agreement), low-burden (one-time, ~$50–200, fast turnaround), and clinically actionable (alternative drug available). The article lands confidently on "if abacavir is being prescribed, test first; if positive, substitute." The broader pharmacogenomic precedent angle is worth surfacing for readers who don't have HIV — the test exemplifies what genotype-guided prescribing looks like when the genetics, the trial evidence, and the alternative drug all line up. Reservations are entirely about overgeneralizing from this case to other (messier) pharmacogenomic targets.
Stakeholder and incentive map
- GlaxoSmithKline / ViiV Healthcare — abacavir's originator and current rights holder. Sponsored PREDICT-1. Screening preserves the drug's market by removing its principal safety liability.
- HIV specialty societies (IAS-USA, BHIVA, EACS, IDSA) — uniformly endorse the test; safety and clinical efficiency aligned.
- CPIC and pharmacogenomic researchers — strong incentive to promote pre-prescription genomic screening as a clinical model; HLA-B*57:01 is the proof-of-concept they cite most often.
- Regulators (FDA, EMA, TGA, Health Canada) — incentive to manage post-marketing safety; FDA labeling change in 2008 was effectively a direct read of PREDICT-1.
- Public payers and insurers — incentive to cover because downstream HSR management is more costly than the screen.
- Clinical genomics labs — modest commercial interest in the test as a billable item.
- Patients — strong incentive to avoid a serious adverse event; no organized counter-position.
Population variability
HLA-B*57:01 allele frequency varies substantially by ancestry Martin et al. 2014:
- European-descent: roughly 5–8%
- South Asian (especially some Indian subpopulations): 5–14%
- Hispanic / Latino: 2–3%
- East Asian: under 1%
- Sub-Saharan African / African American: 1–2.5%
Despite this variation, the test is recommended for all populations because (a) ancestry self-report is unreliable, (b) admixed populations carry intermediate frequencies, and (c) the consequence of missing a positive is severe. The SHAPE study specifically addressed the concern that the marker might be less predictive in non-white populations and found ~100% sensitivity in both white and black patient groups Saag et al. 2008.
Population variability matters for prior probability and cost-effectiveness calculations, not for who should be tested. Sex and age have no documented effect on test performance. Pediatric data are smaller in volume than adult data but consistent.
The test is not relevant outside abacavir prescribing. It does not generalize to other HLA-linked drug reactions — HLA-B*15:02 for carbamazepine (Asian populations), HLA-B*58:01 for allopurinol, HLA-B*13:01 for dapsone — those require separate testing for separate genotypes.
Knowledge gaps
Penetrance. Not all HLA-B*57:01 carriers exposed to abacavir develop clinical HSR. The reason for incomplete clinical penetrance (despite essentially complete immunological priming) is not fully understood — co-stimulatory signals, viral co-infection, host T-cell receptor repertoire, and possibly co-medications may modulate the threshold between subclinical immune activation and full HSR.
Mechanism downstream. While the "altered self" model is established at the molecular level Illing et al. 2012, the precise downstream immunology — which novel self-peptides drive T-cell activation, and which TCR clones expand — is incompletely characterized.
South Asian populations. Allele frequencies in some Indian subpopulations may be higher than in European-descent populations, but prospective trial data from these populations are sparser. Implementation is universal, but the trial evidence base is uneven.
Pediatric and pregnancy data. Most evidence is extrapolated from adult studies. There is no reason to expect different test performance in these groups, but the trial base is smaller.
Generalizability to other HLA-drug associations. Whether the success of HLA-B*57:01 generalizes broadly to other HLA-linked drug reactions remains an open question for the field — most attempts have not produced equally clean genotype-phenotype links or equally usable drug substitutes.
What would change the author's call: essentially nothing short of a re-examination of PREDICT-1 with hidden bias. The screening is so cleanly effective that even a substantial weakening of effect estimates would still leave it as the dominant strategy whenever abacavir is being prescribed.
Audience scope. This test is only a personal action item for people being prescribed abacavir — a subset of people living with HIV. The article is written for that audience first, with a deliberate second-tier framing of the test as a pharmacogenomic precedent for general readers. No audience meta scoping was applied because the literacy value cuts across genders and age bands.
Scoring narrow-population effects. The hardest call was health_short_term and longevity. The substance produces large protective effects, but only within the ~5–8% (European-descent) carrier subset of an already narrow HIV-treatment population. I scored what the test actually delivers when applied to its intended population — landing at 3 for short-term health (preventing a systemic, sometimes hospitalising reaction) and 2 for longevity (real but small population-level mortality reduction, given how rare fatal re-challenge cases were even pre-screening, and how few people are now started on abacavir at all).
Why no contraindications addressing section. The test itself has no contraindications — it's a single sample with no procedural risk. The clinically actionable contraindication is to abacavir, not the test, and that's covered inside stakes and protocol. Adding a section that said "no contraindications" would have been padding.
Declining clinical relevance of abacavir. Abacavir's role in first-line HIV treatment has narrowed considerably as bictegravir/TAF/FTC and other integrase-inhibitor-based regimens have taken over. The article doesn't dwell on this because it doesn't change the test's value when abacavir is prescribed, and the pharmacogenomic-precedent angle remains. Flagged here in case a future editor wants to add a sentence about the changing therapeutic landscape.
Mechanism simplification. The "altered self" / drug-modified peptide repertoire model (Illing 2012, Norcross 2012) is technically nuanced — non-covalent binding in the F-pocket, novel self-peptide loading, T-cell cross-reactivity. The article compresses this to "the drug changes which protein bits the immune system sees on the cell surface." The full mechanism lives in the research dossier; the simplification was deliberate to keep the prose at the friend-test level.
Future-link candidates.
- Abacavir as a standalone entry — would link in both directions.
- HLA-B*15:02 testing before carbamazepine — parallel pharmacogenomic screen, often grouped with this in CPIC guidelines.
- HLA-B*58:01 testing before allopurinol — same family, broader population (gout treatment).
- DPYD testing before fluoropyrimidines — non-HLA pharmacogenomic screen; same precedent.
- CPIC guidelines as a clinical resource — the framework underneath all of these.
Separate-entry candidates. A standalone entry on the broader concept of pre-prescription pharmacogenomic screening would warrant its own write-up. The current entry touches it in payoff and out-of-scope but doesn't try to be the comprehensive treatment.
What was excluded from the article that the brief implied. The brief named "treatment selection" and "prescribing safety" as scope items. Both are covered (treatment selection inside protocol via the tenofovir substitution; prescribing safety inside stakes, history, and the FDA boxed warning thread), but neither got a dedicated section because they fold naturally into the existing addressing sections. The pharmacogenomic-precedent angle from the brief gets its own treatment inside history and payoff.
HLA-B*57:01 Testing Before Abacavir
Cash price approximately $50–$200 in the U.S.; covered by insurance, Medicaid/Medicare, the Ryan White program, and essentially all national health systems globally. Cost-effective by standard willingness-to-pay thresholds (Schackman et al., AIDS 2008).
One-time blood draw or buccal swab ordered as part of routine HIV care. Result returns in 1–7 days and is valid for life — HLA genotype does not change.
Mechanism characterized at molecular level (Illing et al., Nature 2012). Prospective RCT in 1,956 patients showing complete elimination of immunologically confirmed HSR (Mallal et al., NEJM 2008). Multi-ethnic confirmation in SHAPE (Saag et al., CID 2008). FDA boxed warning (2008), CPIC guideline (Martin et al., CPT 2014), and DHHS antiretroviral guidelines all uniformly require pre-prescription screening.
For carriers prescribed abacavir, the test prevents a systemic delayed hypersensitivity reaction (fever, rash, GI, respiratory involvement) that develops within 11 days in roughly 50–60% of HLA-B*57:01-positive patients. PREDICT-1 showed prospective screening eliminated immunologically confirmed HSR (0% vs 2.7% in the unscreened arm) (Mallal et al., NEJM 2008).
Re-exposure to abacavir after an unrecognized HSR can cause a fatal hypotensive crisis; pre-screening era fatalities drove the regulatory response. Screening eliminates this mortality risk for the ~5–8% of European-descent (and variable by ancestry) carriers who would otherwise receive abacavir. Population-level effect is small but the individual-level effect is large.